"Doxorubicin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.
Descriptor ID |
D004317
|
MeSH Number(s) |
D02.455.426.559.847.562.050.200.175 D04.615.562.050.200.175 D09.408.051.059.200.175
|
Concept/Terms |
Adriblastin- Adriblastin
- Adriblastine
- Adriblastina
- Adriablastine
- Adriablastin
DOXO-cell- DOXO-cell
- DOXO cell
- Urokit Doxo-cell
- Urokit Doxo cell
|
Below are MeSH descriptors whose meaning is more general than "Doxorubicin".
Below are MeSH descriptors whose meaning is more specific than "Doxorubicin".
This graph shows the total number of publications written about "Doxorubicin" by people in this website by year, and whether "Doxorubicin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 8 | 21 | 29 |
1995 | 7 | 19 | 26 |
1996 | 9 | 20 | 29 |
1997 | 5 | 16 | 21 |
1998 | 4 | 16 | 20 |
1999 | 9 | 16 | 25 |
2000 | 6 | 23 | 29 |
2001 | 12 | 23 | 35 |
2002 | 10 | 28 | 38 |
2003 | 16 | 24 | 40 |
2004 | 14 | 28 | 42 |
2005 | 11 | 32 | 43 |
2006 | 11 | 32 | 43 |
2007 | 8 | 26 | 34 |
2008 | 11 | 41 | 52 |
2009 | 11 | 38 | 49 |
2010 | 11 | 40 | 51 |
2011 | 7 | 35 | 42 |
2012 | 8 | 27 | 35 |
2013 | 7 | 38 | 45 |
2014 | 7 | 43 | 50 |
2015 | 11 | 46 | 57 |
2016 | 14 | 26 | 40 |
2017 | 9 | 30 | 39 |
2018 | 6 | 36 | 42 |
2019 | 10 | 23 | 33 |
2020 | 6 | 29 | 35 |
2021 | 5 | 25 | 30 |
2022 | 1 | 19 | 20 |
2023 | 2 | 20 | 22 |
2024 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Doxorubicin" by people in Profiles.
-
Mechanisms driving fasting-induced protection from genotoxic injury in the small intestine. Am J Physiol Gastrointest Liver Physiol. 2024 May 01; 326(5):G504-G524.
-
Late Cardiac Toxic Effects Associated With Treatment Protocols for Hodgkin Lymphoma in Children. JAMA Netw Open. 2024 Jan 02; 7(1):e2351062.
-
Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma. Blood Adv. 2023 11 28; 7(22):7141-7150.
-
Circulating microRNAs and Cytokines as Prognostic Biomarkers for Doxorubicin-Induced Cardiac Injury and for Evaluating the Effectiveness of an Exercise Intervention. Clin Cancer Res. 2023 11 01; 29(21):4430-4440.
-
Prognostic impact of lymph node involvement and loss of heterozygosity of 1p or 16q in stage III favorable histology Wilms tumor: A report from Children's Oncology Group Studies AREN03B2 and AREN0532. Cancer. 2024 03 01; 130(5):792-802.
-
Early skeletal muscle loss in adolescent and young adult cancer patients treated with anthracycline chemotherapy. Cancer Med. 2023 11; 12(22):20798-20809.
-
Influence of treatment intensity and medical comorbidities in older adults with peripheral T cell lymphoma. Leuk Lymphoma. 2023 Dec; 64(14):2258-2268.
-
Subsequent female breast cancer risk associated with anthracycline chemotherapy for childhood cancer. Nat Med. 2023 09; 29(9):2268-2277.
-
Real-World Use of Positron Emission Tomography-Computed Tomography and Reported Deauville Scores in Advanced-Stage Classic Hodgkin Lymphoma: A Community Oncology Practice Perspective. JCO Oncol Pract. 2023 Oct; 19(10):860-870.
-
Inhibition of Galectin-9 sensitizes tumors to anthracycline treatment via inducing antitumor immunity. Int J Biol Sci. 2023; 19(14):4644-4656.